Multiple sclerosis journal - experimental, translational and clinical · 2026
Effect of ocrelizumab on rates of retinal atrophy in relapsing multiple sclerosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
McCormack Brenna, Bacchetti Anna, Lin Ting-Yi, Moretti Giulia S, Filippatou Angeliki, Gakis Georgios, O'Donnell Martin Maurice, Lambert Clare McGarvey, Lee Nathanael J, Ecoff Kaitlyn, Davis Simidele, Otero-Duran Gabriel, Gulati Ananya, Didouchevski Adam, Lievers Ernest, Pellegrini Nicole, Ezzedin Omar, Lambe Jeffrey, Moussa Hussein, Fitzgerald Kathryn, Newsome Scott D, Mowry Ellen M, Sotirchos Elias S, Calabresi Peter A, Nourbakhsh Bardia, Saidha Shiv
Аннотация
BACKGROUND: Ganglion cell + inner plexiform layer (GCIPL) atrophy reflects global neurodegeneration and disability in multiple sclerosis (MS). The effect of ocrelizumab, an anti-CD20 monoclonal antibody and highly-effective disease modifying therapy (DMT), on rates of GCIPL atrophy in people with MS remains understudied.
OBJECTIVES: To assess if ocrelizumab attenuates retinal atrophy rates, particularly GCIPL atrophy, and change in clinical measures in people with relapsing MS (PwRMS), and how this compares to natalizumab (another highly-effective DMT), as well as the related anti-CD20 therapy rituximab.
METHODS: PwRMS receiving ocrelizumab, natalizumab, or rituximab, untreated people with progressive MS (PwPMS), and healthy controls underwent Cirrus HD-OCT, 100% and 2.5%-contrast letter acuity (LA) assessments longitudinally. MS participants underwent Expanded Disability Status Scale (EDSS) assessments. Statistical analyses used linear mixed-effects regression models adjusting for age, sex, race, disease duration, optic neuritis history, and interval between DMT initiation and OCT monitoring; accounting for within-subject, inter-eye correlations.
RESULTS: In ocrelizumab-treated PwRMS, GCIPL atrophy rate was -0.15 µm/year (SE = 0.03, p < 0.001, n = 88 [168 eyes]), similar to GCIPL atrophy in natalizumab- or rituximab-treated PwRMS, and healthy controls, although slower than in untreated PwPMS (-0.35 µm/year, SE = 0.04, p < 0.001, n = 40 [78 eyes]). EDSS and LA scores remained stable in ocrelizumab-treated PwRMS, and similar to natalizumab- or rituximab-treated PwRMS.
CONCLUSION: GCIPL atrophy is attenuated and clinical function relatively stable in PwRMS treated with ocrelizumab.
OBJECTIVES: To assess if ocrelizumab attenuates retinal atrophy rates, particularly GCIPL atrophy, and change in clinical measures in people with relapsing MS (PwRMS), and how this compares to natalizumab (another highly-effective DMT), as well as the related anti-CD20 therapy rituximab.
METHODS: PwRMS receiving ocrelizumab, natalizumab, or rituximab, untreated people with progressive MS (PwPMS), and healthy controls underwent Cirrus HD-OCT, 100% and 2.5%-contrast letter acuity (LA) assessments longitudinally. MS participants underwent Expanded Disability Status Scale (EDSS) assessments. Statistical analyses used linear mixed-effects regression models adjusting for age, sex, race, disease duration, optic neuritis history, and interval between DMT initiation and OCT monitoring; accounting for within-subject, inter-eye correlations.
RESULTS: In ocrelizumab-treated PwRMS, GCIPL atrophy rate was -0.15 µm/year (SE = 0.03, p < 0.001, n = 88 [168 eyes]), similar to GCIPL atrophy in natalizumab- or rituximab-treated PwRMS, and healthy controls, although slower than in untreated PwPMS (-0.35 µm/year, SE = 0.04, p < 0.001, n = 40 [78 eyes]). EDSS and LA scores remained stable in ocrelizumab-treated PwRMS, and similar to natalizumab- or rituximab-treated PwRMS.
CONCLUSION: GCIPL atrophy is attenuated and clinical function relatively stable in PwRMS treated with ocrelizumab.